hotspot -WSS

hotspot

author：comprehensive 2025-10-01 11:33:34 - browse：6

NEW ORLEANS — For some patients suffering with certain blood cancers, CAR-T therapy can offer the tantalizing chance to end their disease with a single treatment.

But the immunotherapy takes time to manufacture, and patients often have to wait weeks to actually receive an infusion once they’re eligible. For some patients with especially aggressive cancer, they can die while waiting for the therapy to arrive.

That’s spurred CAR-T manufacturers to find ways to speed up manufacturing. The industry is testing newer — and possibly better — CAR-T cells that can be made more quickly. Researchers working with Novartis presented Phase 1 clinical trial data Sunday on a new CAR-T cell made with a rapid manufacturing process at the annual American Society of Hematology meeting.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： After Sarepta trial failure, Duchenne families brace for more debate

entertainment

focus

WSS

Dems pitch expanding Medicare power to negotiate drug prices

How neuroscience research could help beat back brain cancer

STAT Report: Patient voices and perspectives

Former reverend arrested for allegedly killing 8

Explaining an after

'Investigate these claims': UFO transparency at center of House hearing

explore

hotspot

knowledge

Medical records are filled with copy

Search called off for baby washed away in Pennsylvania flash flood

The cancer drug shortage isn’t new — and neither are the solutions

Gene therapy’s promise and the high cost of hope

Hepatitis C has a cure — but many Americans still lack access to it

Humans aren't the only ones with an imagination. Rats have it too

Hepatitis C has a cure — but many Americans still lack access to it

Bill would allow buprenorphine prescription for addiction via telehealth

Jerome Adams on the need for new antivirals for Covid

New Alzheimer's drugs heat up race for early detection blood tests

hotspot

All of Us, NIH's precision medicine initiative, gets a big boost

Coloradans with cystic fibrosis could lose access to Trikafta

'Investigate these claims': UFO transparency at center of House hearing

What it's like to live with paralysis for one psychologist

What it's like to live with paralysis for one psychologist

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

entertainment

hotspot

focus

knowledge